title: Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison".
authors.forename: M Haim
authors.initials: MH
authors.lastname: Erder
authors.forename: Jipan
authors.initials: J
authors.lastname: Xie
authors.forename: James E
authors.initials: JE
authors.lastname: Signorovitch
authors.forename: Kristina S
authors.initials: KS
authors.lastname: Chen
authors.forename: Paul
authors.initials: P
authors.lastname: Hodgkins
authors.forename: Mei
authors.initials: M
authors.lastname: Lu
authors.forename: Eric Q
authors.initials: EQ
authors.lastname: Wu
authors.forename: Vanja
authors.initials: V
authors.lastname: Sikirica
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000191:economics*; D058647:Adrenergic alpha-2 Receptor Agonists / Q000191:economics*; D001289:Attention Deficit Disorder with Hyperactivity / Q000191:economics*; D005260:Female; D016316:Guanfacine / Q000191:economics*; D006801:Humans; D008297:Male; D011437:Propylamines / Q000191:economics*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D058647:Adrenergic alpha-2 Receptor Agonists; D011437:Propylamines; D016316:Guanfacine